Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
about
Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
P2860
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
@en
type
label
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
@en
prefLabel
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
@en
P2093
P2860
P356
P1476
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy
@en
P2093
Beniamina Gallelli
Elisa Giglio
Federica Depetri
Francesca Brunini
Francesca Raffiotta
Lucia Del Vecchio
Marco D'Amico
Piergiorgio Messa
Renato Alberto Sinico
Selena Longhi
P2860
P304
P356
10.1093/NDT/GFW251
P407
P577
2017-10-01T00:00:00Z